SCHEMBL2593343

SCHEMBL2593343

COC(=O)C(C)(C)COc1c(-c2ccc3c(c2)CNC3=O)ccc(OC)c1OC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 1/20 0.41
POLQ O75417 1/20 0.40
GSK3B P49841 2/20 0.39
PRF1 P14222 1/20 0.39
MAPKAPK2 P49137 1/20 0.38
DAPK3 O43293 1/20 0.38
NTRK1 P04629 1/20 0.38
PIM1 P11309 1/20 0.38
FLT3 P36888 1/20 0.38
ROCK1 Q13464 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
TDP2 O95551 2/20 0.36
TBK1 Q9UHD2 1/20 0.35
BRAF P15056 1/20 0.35
AKT1 P31749 1/20 0.35
TGFBR1 P36897 1/20 0.35
ACVR1 Q04771 1/20 0.35
TARS1 P26639 1/20 0.35
GPR119 Q8TDV5 1/20 0.35
SYK P43405 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2591921 0.92 POLQ (0.39) PRKCIPOLQGSK3BPRF1MAPKAPK2
SCHEMBL2591751 0.92 PRKCI (0.37) PRKCIPOLQGSK3BPRF1MAPKAPK2
SCHEMBL2590153 0.91 PRKCI (0.37) PRKCIPOLQGSK3BPRF1MAPKAPK2
SCHEMBL2592152 0.90 PRKCI (0.36) PRKCIPOLQGSK3BPRF1MAPKAPK2
SCHEMBL2594485 0.89 PRKCI (0.36) PRKCIPOLQGSK3BPRF1MAPKAPK2
SCHEMBL2592192 0.89 GSK3B (0.38) PRKCIPOLQGSK3BPRF1MAPKAPK2
SCHEMBL2589485 0.89 GSK3B (0.38) PRKCIPOLQGSK3BPRF1MAPKAPK2
SCHEMBL2583901 0.89 MAPKAPK2 (0.37) PRKCIPOLQGSK3BPRF1MAPKAPK2
SCHEMBL14737014 0.88 GSK3B (0.36) PRKCIPOLQGSK3BPRF1MAPKAPK2
SCHEMBL2589398 0.88 POLQ (0.35) PRKCIPOLQGSK3BPRF1MAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2563770-B1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2016-03-23 EP disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 US disclosed
EP-2563770-A1 BIARYL PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2013-03-06 EP disclosed
WO-2011134468-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2011-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE4A PRKCI 676/4885POLQ 1717/4885GSK3B 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.